Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received a successful response to its recent Type C meeting request from the U.S ...

For decades, oncologists have watched a frustrating pattern repeat itself. Tumors fueled by the MYC protein, one of the most ...

New NIH research reveals that semaglutide sparks different responses inside appetite-controlling brain cells, offering fresh insight into why GLP-1 weight-loss drugs don’t work the same for everyone.

A single infusion of an experimental gene-editing drug seemed to reduce LDL long-term in a small trial. The results may point to something “curative,” one expert said.

Nicotinamide adenine dinucleotide, or N.A.D.+, has been among the hottest anti-aging supplements for several years. It’s sold ...

Abstract   Title   Presenter   ASCO   Session   Zongertinib   and HER2 PRO results from the Beamion LUNG-1 trial in treatment-naïve patients with ...

A team of researchers at the National Institutes of Health (NIH) have unveiled new details about the events GLP-1 receptor ...

Discover which Ebola treatments are proven effective, how supportive care saves lives, and why early care matters.

Lifestyle intervention remains a core component of obesity management, alongside the emergence of more potent pharmacotherapy ...

Patient preference is an important part of cancer treatment planning, but new research suggests that many women facing ...

The Food and Drug Administration (FDA) on May 22, 2026, approved Datroway (datopotamab deruxtecan-dlnk) for adult patients ...